Neoplasms

All Conditions

Symptoms and General Pathology

Carcinoma

Frailty

All outpatients, age 70 years or more, with solid malignancies, referred to the Department of Oncology at Odense University Hospital for 1st line antineoplastic treatment or information,

The G8 is an eight-item screening tool, developed for older cancer patients. The G8 score ranges from 0 (heavily impaired) to 17 (not at all impaired), with a cut-off for potential frailty of ≤14.

Geriatric 8

The mG8 is a modified version of the Geriatric 8 screening tool, consisting of 6-items. The mG8 score ranges from 0 (not at all impaired) to 35 (heavily impaired), with a cut-off for potential frailty at ≥6.

modified Geriatric 8

30 second chair stand test

Handgrip Strength Test

Marianne Ewertz, MD, DMSc

Jesper Ryg, MD, PhD

Cecilia M Lund, MD, PhD

Trine L Jørgensen, MD, PhD

Per Pfieffer, MD, PhD

Henrik J Ditzel, MD, DMSc

Older patients with cancer constitute a heterogeneous group with varying comorbidity; therefore, geriatric assessment with initial screening is recommended. The Geriatric 8 (G8) has been established as a promising screening tool. Currently, there are no guidelines for oncogeriatric screening in older cancer patients in Denmark. We hypothesize that by screening persons age 70 years or more with newly diagnosed cancer, with the G8, we can assess the prognostic value and identify a subgroup of patients who will benefit from a CGA.

Aims:

* Determine whether Danish cancer patients, with a G8 score of ≤14, experience poorer quality of life (QoL), receive less recommended standard cancer treatment, experience more treatment-related toxicity, stop treatment earlier, and experience shorter survival than patients with a G8 score \>14.
* Ascertain whether the standard G8 cut-off score of ≤14 is the most relevant cut-off score, with respect to treatment adherence, treatment-related toxicity, QoL, and survival, when focusing on the older Danish cancer patient population.
* Establish whether the performance and prognostic value of the G8 can be strengthened through the addition of a functional measure, the 30-second chair stand test (30-CST), and/ or the handgrip strength test (HGST).
* Evaluate the prognostic value of the modified Geriatric 8 (mG8)

Methods:

A prospective, descriptive study of all outpatients with newly diagnosed solid tumors at the Department of Oncology, Odense University Hospital, age 70 years or more. Patients will be screened with the G8, mG8, 30-CST, HGST, and QoL questionnaires at baseline with subsequent one-year follow-up, to determine the prognostic value of the G8 and the mG8. An initial two-month pilot study will help determine inclusion rates and highlight necessary practical adjustments to ensure optimal study participation. Baseline characteristics will be compared with descriptive statistics. Our primary endpoint; Global Health status/ QoL (EORTC QLQ-C30 \& QLQ-ELD14), and secondary endpoints; treatment adherence, and treatment-related toxicity, will be assessed using logistical regression; while secondary endpoints; overall survival, cancer-specific survival, will be assessed using the Kaplan Meier analysis and Cox proportional hazard models. Post hoc diagnostic performance analysis will be conducted to determine the optimal G8 cut-off and whether functional measures (30-CST and HGST) can enhance screening accuracy.

Geriatric Oncology Screening of Older Patients With Solid Cancers

Predictive Value of Geriatric Oncology Screening and Geriatric Assessment in Older Patients With Solid Cancers: A Prospective G8 Study

Global health status will be described using EORTC QLQ-C30

HRQoL is measured by EORTC QLQ-ELD14 (ELderly Cancer Patients Module)

Overall Survival is measured from Geriatric 8 screening to time of death

Cancer-specific Survival is measured from Geriatric 8 screening to time of death in patients with residual cancer

Deviation from initial oncologic treatment plan with the registration of dose reductions, with the given dose measured as a percentage of the planned dose.

Deviation from initial oncologic treatment plan with the registration of dose delays, measured in days.

Deviation from initial oncologic treatment plan with the registration of discontinuation of treatment, measured as the number of given cycles divided by the number of planned cycles.

Performance analysis will be conducted using patients allocated to Comprehensive Geriatric Assessment (CGA), where an abnormal CGA will be defined as \>1 abnormal domain, in accordance with the Danish version of the Geriatric Core Dataset (G-Code).

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Geriatric Oncology Screening of Older Patients With Solid Cancers	NCT04644874	Solid Carcinoma Frailty Age Geriatrics Screening Cancer	Geriatric 8 modified Geriat... 30 second chair... Handgrip Streng...	70 Years -	Odense University Hospital
Geriatric Oncology Screening of Older Patients With Solid Cancers	NCT04644874	Solid Carcinoma Frailty Age Geriatrics Screening Cancer	Geriatric 8 modified Geriat... 30 second chair... Handgrip Streng...	70 Years -	Odense University Hospital

Spots Global Cancer Trial Database for modified geriatric 8